These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 22770604)

  • 61. [Immunogenicity of biopharmaceuticals: Which consequences during the treatment of rheumatoid arthritis?].
    Goupille P
    Rev Med Interne; 2016 May; 37(5):343-9. PubMed ID: 26526777
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comparison of competitive ligand-binding assay and bioassay formats for the measurement of neutralizing antibodies to protein therapeutics.
    Finco D; Baltrukonis D; Clements-Egan A; Delaria K; Gunn GR; Lowe J; Maia M; Wong T
    J Pharm Biomed Anal; 2011 Jan; 54(2):351-8. PubMed ID: 20863644
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Biosimilars: current status and future directions.
    Roger SD
    Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Unraveling the Effect of Immunogenicity on the PK/PD, Efficacy, and Safety of Therapeutic Proteins.
    Smith A; Manoli H; Jaw S; Frutoz K; Epstein AL; Khawli LA; Theil FP
    J Immunol Res; 2016; 2016():2342187. PubMed ID: 27579329
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Strategies for the preclinical and clinical characterization of immunogenicity.
    Koren E; Mytych D; Koscec M; Ferbas J; Gupta S; Moxness M; Swanson S
    Dev Biol (Basel); 2005; 122():195-200. PubMed ID: 16375262
    [No Abstract]   [Full Text] [Related]  

  • 66. A role for protein misfolding in immunogenicity of biopharmaceuticals.
    Maas C; Hermeling S; Bouma B; Jiskoot W; Gebbink MF
    J Biol Chem; 2007 Jan; 282(4):2229-36. PubMed ID: 17135263
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Preclinical risk assessment strategy to mitigate the T-cell dependent immunogenicity of protein biotherapeutics: State of the art, challenges and future perspectives.
    Di Ianni A; Barbero L; Fraone T; Cowan K; Sirtori FR
    J Pharm Biomed Anal; 2023 Sep; 234():115500. PubMed ID: 37311374
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immunological mechanism underlying the immune response to recombinant human protein therapeutics.
    Sauerborn M; Brinks V; Jiskoot W; Schellekens H
    Trends Pharmacol Sci; 2010 Feb; 31(2):53-9. PubMed ID: 19963283
    [TBL] [Abstract][Full Text] [Related]  

  • 69. New approaches to prediction of immune responses to therapeutic proteins during preclinical development.
    Perry LC; Jones TD; Baker MP
    Drugs R D; 2008; 9(6):385-96. PubMed ID: 18989990
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes.
    Sharma B
    Biotechnol Adv; 2007; 25(3):325-31. PubMed ID: 17337334
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Preclinical models used for immunogenicity prediction of therapeutic proteins.
    Brinks V; Weinbuch D; Baker M; Dean Y; Stas P; Kostense S; Rup B; Jiskoot W
    Pharm Res; 2013 Jul; 30(7):1719-28. PubMed ID: 23649852
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Investigation of the immunogenicity of a protein drug using equilibrium dialysis and liquid chromatography tandem mass spectrometry detection.
    Ji QC; Rodila R; Morgan SJ; Humerickhouse RA; El-Shourbagy TA
    Anal Chem; 2005 Sep; 77(17):5529-33. PubMed ID: 16131062
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Structure-immunogenicity relationships of therapeutic proteins.
    Hermeling S; Crommelin DJ; Schellekens H; Jiskoot W
    Pharm Res; 2004 Jun; 21(6):897-903. PubMed ID: 15212151
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Assessing immunogenicity in the presence of excess protein therapeutic using immunoprecipitation and quantitative mass spectrometry.
    Neubert H; Grace C; Rumpel K; James I
    Anal Chem; 2008 Sep; 80(18):6907-14. PubMed ID: 18702532
    [TBL] [Abstract][Full Text] [Related]  

  • 75. From the bench to clinical practice: understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals.
    Gunn GR; Sealey DC; Jamali F; Meibohm B; Ghosh S; Shankar G
    Clin Exp Immunol; 2016 May; 184(2):137-46. PubMed ID: 26597698
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immunogenicity of therapeutic proteins: clinical implications and future prospects.
    Schellekens H
    Clin Ther; 2002 Nov; 24(11):1720-40; discussion 1719. PubMed ID: 12501870
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunogenicity of therapeutic proteins. Part 1: impact of product handling.
    Sharma B
    Biotechnol Adv; 2007; 25(3):310-7. PubMed ID: 17336479
    [TBL] [Abstract][Full Text] [Related]  

  • 78. New FDA draft guidance on immunogenicity.
    Parenky A; Myler H; Amaravadi L; Bechtold-Peters K; Rosenberg A; Kirshner S; Quarmby V
    AAPS J; 2014 May; 16(3):499-503. PubMed ID: 24682766
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics.
    Gupta S; Indelicato SR; Jethwa V; Kawabata T; Kelley M; Mire-Sluis AR; Richards SM; Rup B; Shores E; Swanson SJ; Wakshull E
    J Immunol Methods; 2007 Apr; 321(1-2):1-18. PubMed ID: 17307199
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [The prediction of immunogenicity of therapeutic proteins].
    Maillère B; Delluc S; Ravot G
    Med Sci (Paris); 2012 Jan; 28(1):82-8. PubMed ID: 22289835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.